Legend Biotech Corp.NASDAQ: LEGN

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

· Issued by Legend Biotech Corp. via GlobeNewswire

Summary by 6ix AI

Legend Biotech Corporation, a cell therapy company, will host an investor conference call and webcast at 8:00 a.m. ET on Tuesday, November 10, 2026, to review its third quarter 2026 financial results.

Key details

  • Senior management will give an overview of quarterly financial performance during the call and live audio webcast.
  • A replay of the webcast and the earnings press release will be available in the Investor Relations section of the Legend Biotech website, under Events and Presentations, approximately two hours after the call ends.

6ix AI wrote this summary from the release below and checked it against the release.

BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026, to review third quarter 2026 financial results.

During the conference call and accompanying webcast, senior management will provide an overview of quarterly financial performance.

Investors and other interested parties may access the live audio webcast via this weblink.

A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentations approximately two hours after the conclusion of the call.

ABOUT LEGEND BIOTECH

With over 3,000 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. Legend Biotech is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the United States, Legend Biotech is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, Legend Biotech plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.

Learn more at https://legendbiotech.com and follow us on X, Instagram, and LinkedIn.

INVESTOR CONTACT:
Caroline Paul
Tel: (973) 650-5832
[email protected]

PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
[email protected]

View original source (GlobeNewswire)Legend Biotech Corp. on 6ix

Earlier from Legend Biotech

Later from Legend Biotech

All Legend Biotech news releases